Citronellal methylanthranilate
Common Name: |
Citronellal methylanthranilate |
IUPAC Name: |
methyl 2-(3,7-dimethyloct-6-enylideneamino)benzoate |
Molecular Formula: |
C18H25NO2 |
SMILES: |
CC(CCC=C(C)C)CC=NC1=CC=CC=C1C(=O)OC |
Inchi: |
1S/C18H25NO2/c1-14(2)8-7-9-15(3)12-13-19-17-11-6-5-10-16(17)18(20)21-4/h5-6,8,10-11,13,15H,7,9,12H2,1-4H3 |
Inchi Key: |
FOIQCUQRLOGHEZ-UHFFFAOYSA-N |
Cas No: |
67845-42-5 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
0 |
Name |
Value |
Molecular Weight (g/mol) |
287.40 |
Mass (g/mol) |
287.189 |
Molar Refractivity |
89.72 |
Net Charge |
|
HBD |
|
HBA |
3 |
Rt Bonds |
8 |
Rings |
1 |
TPSA |
38.66 |
Hetero Atoms |
3 |
Heavy Atoms |
21 |
Aromatic Heavy Atoms |
6 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
408.00 to 409.00 |
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.44 |
LogP |
4.948 |
iLOGP |
3.40 |
XLOGP3 |
4.65 |
WLOGP |
4.95 |
MLOGP |
3.87 |
ESOL Log S |
-4.23 |
ESOL Solubility (mg/ml) |
0.017 |
ESOL Solubility (mol/l) |
0 |
ESOL Class: esol_class |
Moderately soluble |
Ali Log S |
-5.19 |
Ali Solubility (mg/ml) |
0 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Moderately soluble |
Silicos-IT LogSw |
-5.08 |
Silicos-IT Solubility (mg/ml) |
0 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Moderately soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-4.75 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.918 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
1 |
CYP2C9 Inhibitor |
1 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
1 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.79 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
0 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
1 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
1 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |